CM
ASMB icon

Crestline Management’s Assembly Biosciences ASMB Stock Holding History

Crestline Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,543
Closed -$89K – 211
2022
Q2 		$89K Sell
3,543
-46
-1% -$1.06K 0.01% 211
2022
Q1 		$89K Buy
+3,589
New +$77K 0.01% 248

Other funds holding ASMB

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Crestline Management's ASMB Position: Q3 2022 in Review

Crestline Management sold out of Assembly Biosciences (ASMB) in Q3 2022, closing a stake of 3,543 shares — an estimated $89K sold.

Crestline Management first reported a position in ASMB in Q1 2022 and held it in 2 quarters. The position peaked at $89K in Q2 2022. 50 funds tracked by Wall St. Rank hold ASMB as of Q3 2022.

  • Crestline Management reported no remaining Assembly Biosciences position as of Q3 2022 after selling out during the quarter.
  • Crestline Management sold 3,543 Assembly Biosciences shares in Q3 2022, an estimated $89K.
  • Crestline Management first reported a position in Assembly Biosciences in Q1 2022 and held it in 2 quarters.
  • Crestline Management's Assembly Biosciences position peaked at $89K in Q2 2022.
  • 50 funds tracked by Wall St. Rank held Assembly Biosciences as of Q3 2022.

Based on Crestline Management's 13F filing for Q3 2022, filed 14 Nov 2022.